T Cell Effector and Regulatory Mechanisms in Asthma
NCT01612936 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 168
Last updated 2017-09-15
Summary
The specific hypothesis for this study is that there are fundamental differences in T effector and T regulatory cell responses in the lung to allergens in allergic asthma (AA) when compared to allergic nonasthmatics (ANA) that account for the difference in clinical responses. We will address this by comparing T cell responses in AA versus ANA subjects. These experiments will correlate T cell responses with measures of airway physiology using state-of-the art lung imaging and examine mechanisms controlling T cell activation in the airways of AA and the function of airway T regulatory cells during AA.
Conditions
Interventions
- BIOLOGICAL
-
Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage
On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A "test dose" concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent.
- PROCEDURE
-
PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Andrew D. Luster, M.D.,Ph.D.
lead OTHER
Principal Investigators
-
Andrew D Luster, M.D., Ph.D. · Massachusetts General Hospital
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-09-30
- Primary Completion
- 2016-09-30
- Completion
- 2016-09-30
Countries
- United States
Study Locations
More Related Trials
-
Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
NCT01420003 ·Status: COMPLETED ·Phase: NA
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
NCT00595491 ·Status: RECRUITING ·Phase: PHASE1
-
Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
NCT02230189 ·Status: COMPLETED ·Phase: PHASE2
-
Cell Biology of Steroid Resistant Asthma
NCT00361920 ·Status: COMPLETED ·Phase: NA
-
Ex Vivo Stimulation of Whole Blood as a Means to Determine Glucocorticoid Sensitivity to Mild-to-Moderate and Refractory Asthmatics
NCT01698983 ·Status: TERMINATED
-
Innate Immunity in Allergic Asthma
NCT06068335 ·Status: RECRUITING
-
Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity
NCT00217854 ·Status: COMPLETED ·Phase: NA
-
Endotoxin and Bronchial Inflammation in Asthma
NCT00005550 ·Status: COMPLETED
-
Imaging Study of the Lungs During an Allergic Asthma Attack
NCT01547286 ·Status: COMPLETED ·Phase: NA
-
Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations
NCT05417906 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Inflammation and Corticosteroid Responsiveness in Severe Asthma
NCT00180661 ·Status: COMPLETED
-
Immune Interactions in Severe Asthma
NCT02566668 ·Status: COMPLETED
-
To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma
NCT02671643 ·Status: COMPLETED
-
Molecular Mechanism of Asthma
NCT00180726 ·Status: WITHDRAWN ·Phase: NA
-
Functional Activity of Airway Eosinophils in Allergic Disease
NCT01026532 ·Status: COMPLETED
-
Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT
NCT00021931 ·Status: COMPLETED
-
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
NCT02502890 ·Status: COMPLETED
-
Role of microRNAs in T Cell-Driven Inflammation in Asthma
NCT01484691 ·Status: COMPLETED ·Phase: NA
-
Isocyanate Antigens and T Cells That Cause Asthma
NCT00005549 ·Status: COMPLETED
-
T Regulatory and Childhood Asthma
NCT00204828 ·Status: COMPLETED
-
An Investigation of Tumor Necrosis Factor (TNF)-Alpha in Asthma Using Biopsy Explants and Primary Bronchial Epithelial Cell Cultures
NCT01161303 ·Status: COMPLETED
-
Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues
NCT00603629 ·Status: COMPLETED
-
The Use of Inflammatory Markers to Guide Therapy in Children With Severe Asthma
NCT00262340 ·Status: COMPLETED ·Phase: NA
-
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
NCT01362621 ·Status: COMPLETED
-
Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils
NCT01366521 ·Status: COMPLETED ·Phase: PHASE2